about
Post-acute care: the role of natriuretic peptidesThe role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for useNatriuretic peptide testing for predicting adverse events following heart failure hospitalizationNatriuretic peptides as biomarkers in heart failureState of the Art: Newer biomarkers in heart failureAsk the doctor. Every day I take a baby aspirin (81 milligrams) that is coated to protect my stomach. Out of curiosity, I dropped a tablet into a glass filled with equal parts water and vinegar. Two days later, it hadn't dissolved. That has me wondeTroponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure SectionST2: a novel remodeling biomarker in acute and chronic heart failureSoluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failureSerial sampling of ST2 predicts 90-day mortality following destabilized heart failureCharacteristics of the novel interleukin family biomarker ST2 in patients with acute heart failurePrognostic significance of elevated cardiac troponin-T levels in acute respiratory distress syndrome patientsPrognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome.Design and baseline data from the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized controlled trial.Design and baseline data from the Gratitude Research in Acute Coronary Events (GRACE) studyCase records of the Massachusetts General Hospital. Case 28-2007. A 68-year-old man with syncope.Characteristics and in-hospital outcomes of patients with cardiac tamponade complicating type A acute aortic dissection.Characterization and prediction of adverse events from intensive chronic heart failure management and effect on quality of life: results from the pro-B-type natriuretic peptide outpatient-tailored chronic heart failure therapy (PROTECT) study.Natriuretic Peptide testing in primary carePlasma C-reactive protein levels are associated with improved outcome in ARDS.High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomographyThe relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes.Depression and failure of cholesterol lowering after acute myocardial infarctionUsefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure.Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.Fatty Acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic strokeClinical and genetic correlates of growth differentiation factor 15 in the communityThird universal definition of myocardial infarction.Comparison of symptoms, treatment, and outcomes of coronary artery disease among rheumatoid arthritis and matched subjects undergoing percutaneous coronary intervention.QTc prolongation, torsades de pointes, and psychotropic medications.Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.Charting a roadmap for heart failure biomarker studies.Relation of natriuretic peptides and midregional proadrenomedullin to cardiac chamber volumes by computed tomography in patients without heart failure: from the ROMICAT TrialThe prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure.Evidence of uncoupling between renal dysfunction and injury in cardiorenal syndrome: insights from the BIONICS study.Plasma and dietary magnesium and risk of sudden cardiac death in women.Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.Myocardial injury and ventricular dysfunction related to training levels among nonelite participants in the Boston marathon.Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study.
P50
Q26852607-75B4558B-7531-4953-AC30-809717D49E47Q27000715-B4E0D792-C359-4201-B3D9-41161136D9FCQ27008553-C9B6ED70-73D8-46F2-BE29-4820DFA71B65Q27012872-13A22D31-4455-416C-8F8F-E634E3F1A9ECQ27027899-2C510C5D-60D4-4B83-9AE4-3F1CDBBFCF47Q28171241-49C78C47-AA93-4F3A-A03A-F5F330D24CD4Q28269814-D1551AB2-217B-49CC-84E8-B973CB06E641Q28280799-2ABCEBFB-B094-4D4F-B953-9884838A1D85Q28294246-3E2C00AC-318F-4EFD-B2E1-0832198F8AF2Q28300297-04E2799E-B010-44B6-9BD8-FEB8731D6386Q28301242-F53EACBE-176A-43A8-9A86-7871808FEA58Q28481296-BE2189E3-0DB9-40AA-8DAF-8C4DFCAFC303Q30409730-D2D32530-FF3E-44A1-9AA0-4AE0C52F9B4CQ30671247-FEA45B60-D30C-4282-AA86-2E979FA898B1Q30979831-0EC720D0-E396-41A8-B776-3089FAE52C04Q33155508-2AEE94EB-D4FF-4CB1-8F19-35EEADCE6856Q33157243-78428D99-C29D-42CE-BAB7-F033F63CA03DQ33165022-7296CEDE-4EA5-4ADF-A604-4B8DA82439C4Q33572286-498B0C70-4C09-4CF8-B1D8-6A7C4D51DA09Q33637609-FD585C19-C73C-4B5D-9573-83FDA573C30FQ33821446-7FA99BA3-B209-46D2-9C3C-F9FB83308B4BQ33868089-2C367A35-205F-4560-BF7F-101227712E34Q33902271-87E5CA2A-B6CE-4348-A955-66F7EBB88C46Q33912126-A5725CA3-A096-461F-B31E-1FB736759381Q34017373-B684CAC3-0856-4BDC-B1CC-5E8AEFE99ADDQ34032111-B767970A-D75A-4556-A399-1B175F135EB5Q34103370-B92A3E37-64F3-4685-B28F-B58ECA8BC53AQ34114806-E537405B-E410-45B2-8F72-FA799C7411A5Q34295914-026492BA-6A34-4B8D-952F-930C389AF21FQ34316084-FD744209-ED6B-45C9-A3E5-2F5490E6E183Q34321193-31981E91-917B-43BF-B5E6-45DD602E8188Q34324771-2348958E-06F0-4FB8-A3D2-9A33BBA58F08Q34324812-84E5C8EF-C862-49D9-9591-6F3D9F68D57BQ34381858-A28D621E-F5C4-4305-BD52-94A674FEE5CCQ34408467-59193C8F-F350-4CC9-AB87-FC2121D10318Q34489305-F695A578-5AEB-43C5-A25F-FC0EF348000FQ34492956-C171245A-97BB-4743-810F-6E08B305C667Q34566520-D9244CE0-FE2E-4ED0-AF89-95011D7C7F1CQ34581341-B874D28E-1BF9-4DF4-8D12-D8FCC2191270Q34622450-0690AE7F-60A1-4210-99BA-AB6484E67FBB
P50
name
James L Januzzi
@ast
James L Januzzi
@en
James L Januzzi
@nl
type
label
James L Januzzi
@ast
James L Januzzi
@en
James L Januzzi
@nl
prefLabel
James L Januzzi
@ast
James L Januzzi
@en
James L Januzzi
@nl